Human Immunodeficiency Virus



A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment


Condition:   Human Immunodeficiency Virus
Interventions:   Biological: Ad26.Mos4.HIV;   Biological: MVA-Mosaic;   Biological: Clade C gp140 + Mosaic gp140;   Drug: Placebo
Sponsors:   Janssen Vaccines & Prevention B.V.;   Beth Israel Deaconess Medical Center;   Ragon Institute;   Military HIV Research Program
Not yet recruiting


A Combination HIV Prevention Strategy for Young Women at Risk for HIV


Condition:   Human Immunodeficiency Virus
Intervention:  
Sponsor:   Columbia University
Recruiting


Partners-based HIV Treatment for Couples Attending Antenatal Care


Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Couples-based services
Sponsors:   Vanderbilt University Medical Center;   National Institute of Mental Health (NIMH)
Not yet recruiting


Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk


Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Provision of multiple self-tests
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Mental Health (NIMH);   Impact Research & Development Organization;   RTI International
Recruiting


Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults


Condition:   Human Immunodeficiency Virus
Interventions:   Biological: Ad26.Mos.HIV;   Biological: MVA-Mosaic;   Drug: Placebo
Sponsor:   Janssen Vaccines & Prevention B.V.
Recruiting


3BNC117 and 10-1074 in HIV Uninfected Adults


Condition:   Human Immunodeficiency Virus
Interventions:   Drug: 3BNC117;   Drug: 10-1074;   Drug: Placebo
Sponsor:   Rockefeller University
Active, not recruiting


A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies


Condition:   Human Immunodeficiency Virus Type 1
Intervention:   Drug: Rilpivirine
Sponsor:   Janssen Sciences Ireland UC
Recruiting


Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen


Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: Subjects do not receive study medication in this study 202094
Sponsors:   ViiV Healthcare;   Janssen, GlaxoSmithKline (GSK)
Active, not recruiting


Regular HIV Testing Among At-Risk Latino Men


Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Behavioral: Social Network;   Behavioral: Comparison
Sponsors:   Medical College of Wisconsin;   National Institute of Mental Health (NIMH)
Enrolling by invitation


Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)


Condition:   Human Immunodeficiency Virus
Interventions:   Behavioral: Cognitive-Based Compassion Training (CBCT);   Behavioral: Health discussion
Sponsor:   Emory University
Completed


Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART


Conditions:   Acquired Immunodeficiency Syndrome;   Human Immunodeficiency Virus Type
Intervention:  
Sponsor:   Olayemi Osiyemi MD
Completed


Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants


Condition:   Human Immunodeficiency Virus Type 1
Interventions:   Drug: D/C/F/TAF;   Drug: Boosted Protease Inhibitor (bPI);   Drug: FTC/TDF
Sponsor:   Janssen R&D Ireland
Active, not recruiting


Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: 744 Tablet;   Drug: 744 LA Injection;   Drug: Placebo Tablet;   Drug: Placebo Injection
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed


HIV Non-Occupational Post-Exposure Prophylaxis


Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Sponsors:   Kenneth H. Mayer, MD;   Gilead Sciences
Completed


Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)


Condition:   Human Immunodeficiency Virus
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Terminated


Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus


Condition:   HIV
Interventions:   Drug: antiretroviral therapy;   Behavioral: cell phone reminders;   Behavioral: contingency management for adherence
Sponsors:   UConn Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting


Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection


Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Busulfan;   Biological: Cal-1 modified HSPC;   Biological: Cal-1 modified CD4+ T lymphocytes
Sponsor:   Calimmune, Inc.
Active, not recruiting


CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)


Condition:   Human Immunodeficiency Virus
Interventions:   Device: Intervention Arm (computer-based CARE+ Corrections tool);   Other: Educational video on opiate overdose prevention
Sponsors:   George Washington University;   The Miriam Hospital;   New York University
Completed


Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Active, not recruiting


Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)


Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: NRTIs;   Drug: Efavirenz
Sponsor:   Janssen-Cilag G.m.b.H
Completed


HIV Persistence and Viral Reservoirs


Conditions:   HIV;   HIV Infections
Intervention:   Drug: Raltegravir, tenofovir/emtricitabine
Sponsors:   University of California, San Francisco;   California HIV/AIDS Research Program;   Gilead Sciences;   Merck Sharp & Dohme Corp.
Unknown status


Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1


Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: BMS-663068 with or without ritonavir
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed


An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children


Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Active, not recruiting


Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1


Condition:   Human Immunodeficiency Virus
Interventions:   Drug: 3-drug anti-HIV therapy;   Drug: Raltegravir
Sponsors:   University of Washington;   Merck Sharp & Dohme Corp.
Terminated


Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients


Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: GI265235
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed

Refine Your Search Advanced Search